Sekeres Mikkael A
Hematology and Medical Oncology - Leukemia Program, Cleveland Clinic, 9500 Euclid Avenue, Desk CA-60, Cleveland, OH 44195, USA.
Best Pract Res Clin Haematol. 2018 Dec;31(4):346-350. doi: 10.1016/j.beha.2018.09.001. Epub 2018 Sep 20.
Therapies for myelodysplastic syndromes (MDS) are chosen depending on whether a patient has lower- or higher-risk disease. Hypomethylating agents are recommended as up-front therapy for all higher-risk patients, and lower-risk patients with multiple cytopenias. This article reviews the rationale for hypomethylating agents, their use or intensive chemotherapy pre-transplant, and data supporting pre-transplant MDS treatment.
骨髓增生异常综合征（MDS）的治疗方案是根据患者疾病风险高低来选择的。对于所有高危患者以及伴有多种血细胞减少的低危患者，推荐使用去甲基化药物作为初始治疗。本文综述了使用去甲基化药物的理论依据、其在移植前与强化化疗联合使用的情况，以及支持移植前MDS治疗的数据。
